COMPANY 2017-10-18T18:28:12+00:00

IQ Medical Ventures B.V. is a subsidiary of RHO-dam Ventures BV; a holding company founded to umbrella two companies which are or will be occupied with the commercialization of technology; health care technology.

The two companies both focus on the commercialization process of technology but from a different angle: Licensing and/or Venturing (& Financing).

The main focus of our company is on IQ-Medical Ventures B.V.; a medical device incubator company, founded to overcome the traditional draw backs of licensing technology to the larger industry. The three layer incubator is founded to generate sales, to establish recognizable sustainable branding and to create value.

We focus on our own product companies to generate sales from medical devices we take from concept to market share. We strive to start up a pallet of marketing/branding companies (IQ-companies) in different areas of the medical market in order to spread our risk and to increase our rate of success. The goal of our IQ-companies is to establish product subsidiaries with a recognizable market position in certain areas of  the medical health care market with their innovative products for unmet needs. All marketed under a recognizable IQ-branding umbrella.

To date we have three products in the market. In gynaecology; GIS®-kit, a system for the extension of the uterine cavity to facilitate virtual Hysteroscopy to detect uterine abnormalities in a less invasive way. ExEm® Foam Kit, a system to provide the gynaecologist with information about tubal patency of her/his patient without X-Ray or the use of the OR. GIS catheter, a versatile catheter to provide access to the uterine cavity to apply any kind of medium suitable for intrauterine examination purposes. In anaesthesia we developed EZ-Blocker, an elegant bifurcated endobroncheal blocking device for providing one lung ventilation in thoracic surgery/anaesthesia, which product we sold in 2012 to another medical device company. Currently (October 2017) we have two products in development, one in angioplasty and one in obstetrics.

ID-NL Patents & Licensing B.V. is a traditional technology transfer company which focuses on patenting and licensing of technology to the larger industry. It is currently occupied with the commercialization of the patents and knowhow of a gyneacological technique called morcelation. The objective is to remove polyps and myoma’s from the uterine cavity.

One of the major licensed technologies to date is the Angioseal® by Dr. Rienks and Dr. Muijs van der Moer. A technology to close off the artery after a “Dotter” procedure to prevent excessive bleeding, currently sold and marketed by St Jude medical out of the USA. Sales has exceeded $ 1,5 billion.